Product Description: BAY-9835 is a potent and orally active ADAMTS7 and ADAMTS12 antagonist with IC50s of 6 nM and 30 nM, respectively. BAY-9835 is very selective against a range of off-targets and metalloproteases. BAY-9835 can be used for the atherogenesis research[1].
Formula: C22H16F5N5O3
References: [1]Daniel Meibom, et al. BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor. J Med Chem. 2024 Feb 22;67(4):2907-2940.